The neurotoxin 6-OHDA has been widely used to model different aspects of PD in rodents. Molecules of 6-OHDA enter neurons by using the catecholamine uptake mechanisms and kill neurons through the formation of free radicals mediated by the inhibition of mitochondrial complexes I and IV. 8, 9 Unilateral administration of 6-OHDA into the SN or the medial forebrain bundle selectively destroys dopamine neurons and decreases dopamine levels in the ipsilateral striatum. In these models, 6-OHDA induces extensive neuronal death within several hours of administration followed by striatal dopamine fiber degeneration during the 1st week postadministration. 14, 18 The unilateral nigral lesion induces a motor asymmetry that can be quantified using the characteristic rotational response to dopamine agonists. 34, 35 Once the lesion is made, this model is useful to evaluate dopamine replacement therapies such as neurotransplantation. Obviously, this model requires experience and skill to target the optimal site. In actuality, the lesions are often varied in size and must be evaluated according to drug-induced rotational behavior before therapeutic intervention. In addition, it provides only a narrow therapeutic window to evaluate a neuroprotective tool because of the quick death of the nigral neurons. 15 In contrast, injection of 6-OHDA into the striatum induces delayed and progressive death of dopamine neurons in the SN during a period of 4 to 6 weeks. 13, 30 The time span between 6-OHDA administration and neuronal death provides a wider therapeutic window to test neuroprotective strategies. 12, 29, 31 As established by Sauer and Oertel, 30 degeneration of the nigral neurons can be monitored with the injection of a neuronal tracer, Fluoro-Gold, prior to the 6-OHDA lesion. It is also known, however, that neuronal death occurs in the limited nigral neurons that project axons Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease to the central striatum. 30, 31 This partial lesion model therefore involves morphological and functional regeneration of dopamine neurons adjacent to affected neurons. In this striatal lesion model, changes in rotational behavior are not apparent because 40 to 50% of the dopamine neurons are preserved in the SN. 6, 13, 30 This study was designed to improve the distribution of 6-OHDA in the rat striatum by using the CED method and to evaluate the development of dopamine lesions. Convection-enhanced delivery is a method of drug delivery developed at the National Institutes of Health. It allows extensive and homogeneous distribution of higher doses of drugs in the brain by using a pressure gradient. Convection-enhanced delivery can be used for efficient conveying of therapeutic agents, such as neurotrophic factors, enzymes, biological modifiers, and genetic vectors, which do not readily cross the blood-brain barrier, into the brain parenchyma. 2, 3, 7, 20 We also conducted further studies to determine whether apoptotic neuronal death was involved in this lesion. It has recently been demonstrated that 6-OHDA induces apoptotic cell death of nigral neurons both in vitro and in vivo. 21, 23, 37 Inhibition of apoptosis might be of therapeutic interest in PD based on postmortem evidence in patients with PD who died.
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Materials and Methods
Lesioning With 6-OHDA by Using CED
Adult Sprague-Dawley rats (Taconic Farms, Taconic, NY), each weighing from 230 to 270 g at the beginning of this experiment, were housed in a 12-hour light/dark cycle with free access to food and water. All animal procedures were completed following the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the National Institute of Neurological Disorders and Stroke's Animal Care and Use Committee.
Data from a previous study showed extensive distribution of 20 l of phaseolus vulgaris-leukoagglutinin (large molecules) over the rat striatum by CED at a rate of 0.1 l/minute. 20 We infused 20 l of 6-OHDA solution at a rate of 0.2 l/minute. For CED of 6-OHDA, 20 l of 0.2% L-ascorbic acid/0.9% saline containing 6-OHDA hydrobromide (5, 10, and 20 g calculated as free base; Sigma Chemical Co., St. Louis, MO) was loaded into polymer tubing (outer and inner diameter 0.06 and 0.03 in, respectively; Upchurch Scientific, Oak Harbor, WA) attached to a gas-tight 1-ml Hamilton syringe filled with mineral oil. A cannula consisting of a fused silica capillary (outer and inner diameter 164 and 100 m, respectively; Polymicro Technologies, Phoenix, AZ) fitted into a 27-gauge needle was connected to the distal end of the polymer tubing. Anesthesia was induced with 5% isoflurane in O 2 flow and maintained with 1% isoflurane in O 2 flow (2 L/minute) with a mask fixed to the stereotactic frame (Kopf, Tujunga, CA). A burr hole was made with a dental drill and the cannula was inserted vertically into the caudate putamen at the following stereotactic coordinates 26 : 0.7 mm anteroposterior to and 2.8 mm lateral to the bregma; Ϫ5 mm ventral to the dura mater (incisor bar set at Ϫ3.3 mm). Twenty microliters of each solution (0, 5, 10, and 20 g of 6-OHDA) was infused at a rate of 0.2 l/minute by using a programmable pump (Bioanalytical Systems, West Lafayette, IN). The control animals were infused with vehicle. The cannula was left in place for 10 minutes and then slowly retracted. To compare CED with conventional microinjection methods, 20 g of 6-OHDA dissolved in 2.8 l of vehicle was slowly injected into the caudate putamen of the additional 12 animals at the same stereotactic coordinates by using a 5-l Hamilton syringe with a 28-gauge needle. Animals were killed at the following time points: 3 days, 1 week, 2 weeks, 4 weeks, and 8 weeks postlesion.
The animals (five-six in each group) that were allowed to survive for 8 weeks postlesion were tested every other week for d-amphetamine (5 mg/kg subcutaneously; Sigma) and apomorphine (0.25 mg/kg subcutaneously; Sigma) rotational response. Rotations were quantified using an automated rotometer system run on a Macintosh computer (Rotate 1.6; National Institutes of Health, Bethesda, MD).
Retrograde Labeling of Nigral Neurons
To estimate the distribution of the solution infused using the CED method, nigrostriatal neurons were retrogradely labeled with FluoroGold (Fluorochrome, Denver, CO) in a separate group of animals by using an identical infusion procedure. To minimize nonspecific tissue damage in the striatum, a lower concentration of Fluoro-Gold solution (0.05%, 20 l) was infused into the striatum at the same stereotactic coordinates as the 6-OHDA infusion. These animals were killed at 24 hours (two animals) and 5 days (four animals) after Fluoro-Gold infusion.
Histopathological Procedures
Animals were deeply anesthetized with an intraperitoneal injection of pentobarbital (150 mg/kg) and transcardially perfused with 0.1 M PBS (pH 7.4), followed by 200 ml of 4% paraformaldehyde dissolved in PBS. The brains were removed, postfixed overnight, and equilibrated in graded sucrose (20-30%) solutions. The brains of the rats allowed to survive for 8 weeks were removed immediately after anesthesia was induced, chilled in ice-cold PBS, and placed on a brain blocker (Kopf). The striatum was sliced into 1-mm-thick coronal sections, frozen on dry ice, and stored at Ϫ80˚C until biochemical analysis. The midbrain was immersion-fixed in 4% paraformaldehyde at 4˚C for 3 days, and cryoprotected by graded sucrose (20-30%) dissolved in 4% paraformaldehyde. Coronal sections (30 m thick) of the striatum and midbrain were cut on a cryostat and collected serially in an antifreezing solution. Every sixth section of the striatum and the SN were processed for TH immunohistochemistry by using anti-TH antibody (mouse monoclonal antibody, 1:1000; Chemicon, Temecula, CA). Staining was performed on free-floating sections, as described in a previous report. 2 Sections were mounted on gelatin-coated slides and coverslipped with mounting medium (Permount; Fisher Scientific, Suwanee, GA). Nigral sections were counterstained with Nissl stain. Sections of the SN were also processed for TH immunofluorescence. After incubation in anti-TH antibody (1:300), sections were incubated in rhodamine-conjugated anti-mouse immunoglobulin-G (1:50; Jackson ImmunoResearch Labs, West Grove, PA) for 3 hours. Sections were then mounted, counterstained with Hoechst 33342 (10%; Sigma), and coverslipped in Gel Mount (Biomeda, Foster City, CA).
Neuronal loss in the striatum was analyzed using the nuclear neuronal marker NeuN. 25 Every 12th section of the striatum was stained with anti-NeuN antibody (mouse monoclonal antibody, 1: 300; Chemicon).
Apoptotic Cells
To identify apoptotic cells, nigral sections were processed for ISEL of free 3Ј-OH ends in fragmented nuclear genomic DNA. Nucleotides labeled with fluorescein were enzymatically added to the DNA by TdT according to the manufacturer's specifications (ApopTag Fluorescein Kit; Intergen, Norcross, GA). Briefly, every sixth section of the SN was postfixed in ethanol/acetic acid (2:1) for 5 minutes at Ϫ20˚C and incubated in the mixture of TdT and reaction buffer containing the fluorescein nucleotide for 1 hour at 37˚C. Sections were mounted and counterstained with Hoechst 33342. Apoptotic labeled cells were counted in every 12th section taken from levels Ϫ4.8 mm to Ϫ6.3 mm anteroposterior to the bregma according to the atlas 26 with the aid of 200ϫ magnification. The prevalence of apoptotic profiles was also determined on THimmunoreactive cells by using Nissl counterstain, as previously described. 23 Apoptotic profiles were defined by the presence of one or more intensely basophilic, rounded, and distinct chromatin clumps within the nuclei. Also, nigral sections processed for TH immunofluorescence and counterstained with Hoechst 33342 were observed with the aid of a confocal microscope (Axiovert LSM 400 station; Zeiss, Oberkochen, Germany) to confirm colocalization of chromatin clumps in TH-immunoreactive neurons.
Quantitative Morphological Analysis
Unbiased stereological procedures were performed using the optical dissector method to estimate the total number of TH-immunoreactive neurons in the SN and VTA. 10, 36 All analyses were performed using appropriate software (NeuroZoom, La Jolla, CA), as described in a previous report. 2 Every sixth section was taken from levels Ϫ4.8 mm to Ϫ6.3 mm anteroposterior to the bregma according to the atlas. 26 The anatomical landmarks used to delineate the SN from the VTA were the rootlets of the oculomotor nerve rostrally and the medial lemniscus caudally.
The number of neurons was also estimated on sections counterstained with Nissl to determine the extent of neuronal loss (as opposed to TH downregulation) in the SN. Neuronal nuclei were identified as round, vesicular nuclei with prominent nucleoli, whereas glial cells were visualized as small hyperchromatic, oval-or spindleshaped nuclei. The pars compacta of the SN was delineated in every sixth section, and neuronal nuclei were counted in more than 20% of the contour areas by using a 63ϫ objective. Neuronal densities (counts per mm 2 ) were compared between the lesioned side and the contralateral nonlesioned side, and neuronal loss was expressed as a percentage of the contralateral side.
The NeuN-positive cells were counted using stereological procedures to evaluate nonspecific neuronal loss in the striatum 4 weeks after the 6-OHDA lesion. Striatal neuronal loss was also expressed as a percentage of that on the contralateral side.
Dopamine Concentration in the Striatal Regions
Punches from the anterior and middle striatum and from the nucleus accumbens were processed for HPLC. At 8 weeks postlesion immediately after inducing a deep anesthesia with an intraperitoneal injection of pentobarbital (150 mg/kg), the animals were decapitated. The anterior and middle striatum and the nucleus accumbens were punched from the 1-mm-thick slices obtained from levels 2.2 mm and 0.2 mm anteroposterior to the bregma according to the atlas. 26 The punch diameter was 1 mm. The frozen micropunches were homogenized in 500 l of 0.1 M perchloric acid (Fisher Scientific) containing 1% ethanol and 0.02% disodium ethylenediamine tetraacetic acid (Fisher Scientific). Dopamine was measured using HPLC with the aid of an Ultrasphere C-18 ion pair column, 5 m, 4.6 mm ϫ 25 cm (model no. 23532; Beckman Coulter, Fullerton, CA). The amperometric electrochemical detector (CB-100; EiCom, Kyoto, Japan) was set at 0.78 V. The mobile phase was the same as that described previously. 19 The results were recorded and analyzed using a chromatography manager (Millennium 2010; Waters, Milford, MA). The protein content in each tissue sample was determined using the BCA protein assay kit (Pierce, Rockford, IL). Concentrations of dopamine, DOPAC, and HVA were expressed in nanograms per milligram of protein.
Statistical Analysis
Data are reported as the means Ϯ SEM. A paired t-test was used for comparison of the data between the lesioned and nonlesioned sides. A two-way ANOVA followed by a Scheffé post hoc test were used to compare stereological data among the groups receiving different 6-OHDA doses. The biochemical data at 8 weeks postlesion was compared between the groups of different 6-OHDA doses by calculating one-way ANOVA. The turning behavior was analyzed using a two-way ANOVA with repeated measures for time and drug effects. Statistical significance was defined at a probability value less than 0.05.
Results
Extensive, Progressive, Dose-Dependent Degeneration of the Nigrostriatal Pathway
Striatal Dopamine Lesion. Serial analysis of TH-immunoreactivity showed that the decrease in dopamine terminals had already started by 3 days postlesion. The extent of denervation was related to the dose of 6-OHDA. At 4 weeks postlesion (Fig. 1A) all TH-immunoreactive fibers were depleted in almost the entire striatum of rats receiving 20 g of 6-OHDA, whereas dopamine terminals were relatively spared following 10-and 5-g doses. The TH-immunoreactive fibers were relatively preserved in the nucleus accumbens and olfactory tubercle in all groups. No decrease of TH innervation was observed in the control rats.
Stereological counts of NeuN-immunoreactive cells in the striatum confirmed the absence of significant neuronal damage after CED. Four weeks after lesioning, only small areas along the cannula track showed a decrease in NeuN immunoreactivity (Fig. 1B) . Quantitative analysis demonstrated 99.7 Ϯ 6.6%, 101 Ϯ 5.3%, 94.5 Ϯ 6.9%, and 90.1 Ϯ 5.2% NeuN-positive cells with respect to the contralateral side for 0, 5, 10, and 20 g of 6-OHDA, respectively (p Ͼ 0.05).
Retrograde Labeling of Nigral Neurons. To ensure that striatal CED administration of 20 g of 6-OHDA solution targeted the nigral dopamine neurons and to estimate the extent of distribution of the solution infused with CED, we examined the distribution of the same volume of FluoroGold solution infused in the same manner. Fluoro-Gold deposits covered the entire striatum with moderately necrotic areas in the center of the infusion sites 24 hours after infusion ( Fig. 2A and B) . The ventral striatum, corresponding to the nucleus accumbens and olfactory tubercle, had less Fluoro-Gold deposits. Extensive labeling was observed in the ipsilateral midbrain 5 days after Fluoro-Gold infusion (Fig. 2C-E) when the central necrosis of the striatal infusion sites increased in size. In the pars compacta of the SN (A9) more than 80% of the TH-immunoreactive cells were Fluoro-Gold-positive (Fig. 2C) . In the VTA (A10) 32 to 51% of the TH-immunoreactive cells were Fluoro-Goldpositive at the level of the paranigral nucleus (Fig. 2D) and fewer than 30% were Fluoro-Gold-positive in the interfascicular nucleus (Fig. 2E ). More cells (55-74% of THimmunoreactive cells) were labeled with Fluoro-Gold in the retrorubral area (A8) than in the VTA. Few cells (one to four cells/section) were labeled in the contralateral SN and VTA.
Nigral 6-OHDA Lesion. Representative photomicrographs and stereological counts of the TH-immunoreactive cells of the SN are shown in Fig. 3 and Table 1 , respectively. Intrastriatal infusion of 6-OHDA induced a progressive and dose-dependent loss of the TH-immunoreactive cells in the ipsilateral SN. In the rats receiving 6-OHDA, the THimmunoreactive cells significantly decreased subsequent to 1 week postlesion (ANOVA F 4,71 = 27.8, p Ͻ 0.0001). Dosedependent decreases in the TH-immunoreactive cell counts were observed in the SN on the lesioned side (ANOVA F 3,49 = 20.4, p Ͻ 0.0001). At 1 week postlesion, significant decreases in TH-immunoreactive cell counts were seen in the SN receiving 10 and 20 g of 6-OHDA, whereas the cell loss had not started at 3 days postlesion. The TH-immunoreactive cell loss in the SN started 1 week postlesion and progressed for 8 weeks. No significant loss in the TH-immunoreactive cell count was observed on the contralateral nonlesioned side when the total cell numbers were compared in the control (vehicle-infused) animals. Therefore, as demonstrated in a previous study, 30 a percentage of cells on the contralateral side, the cell survival rate, was also used for comparison between the groups and the time points (Fig. 4A and B) . The statistical significance was similar when the cell survival rates were compared. Fluoro-Gold distributed over the striatum 24 hours after CED. B: Fluoro-Gold deposits covered the entire striatum 24 hours after CED, whereas they were sparse outside the striatum. C: In the pars compacta of the SN more than 80% of TH-immunoreactive neurons were labeled 5 days after Fluoro-Gold infusion. D: In the paranigral nucleus of the VTA, fewer than 50% of cells were labeled. E: In the interfascicular nucleus of the VTA, fewer than 30% of TH-immunoreactive neurons were Fluoro-Gold-positive. CC = corpus callosum; Str = striatum.
after lesioning, the TH-immunoreactive cell numbers significantly decreased to 55.3 Ϯ 6.1%, 36.2 Ϯ 4.6%, and 17.2 Ϯ 4.7% of the contralateral SN with 5, 10, and 20 g of 6-OHDA, respectively (Fig. 4A) . The rates of cell survival were significantly different between the animals receiving 0 and 5 g, 5 and 10 g, and 10 and 20 g of 6-OHDA. In the VTA, however, the decrease in TH-immunoreactive cells was significant only in the group receiving 20 g of 6-OHDA at 8 weeks postlesion (70.7 Ϯ 3.8%; Fig. 4B ). In the group receiving 20 g of 6-OHDA we examined the rate of neuronal loss to differentiate TH downregulation from actual cell death (Fig. 4C) One week after the 6-OHDA lesions, apoptotic profiles were observed in nigral sections processed for TH immunohistochemistry with Nissl counterstain. Apoptotic dopamine neurons were identified by a TH-immunostained cytoplasm encircling an apoptotic nuclei as defined by one or more intensely basophilic, rounded, sharply delineated chromatin clumps with Nissl counterstain (Fig. 5A) . 22, 23 Apoptotic nuclei were occasionally observed in the THnegative cells (Fig. 5B) . The presence of apoptotic nuclei in the TH-immunoreactive neurons was confirmed with the aid of confocal microscopy of the TH-immunofluorescent sections counterstained with the nuclear dye Hoechst 33342 (Fig. 5C and D) and with ISEL ( Fig. 5E and F) . Quantitative analysis revealed significant numbers of ISEL-positive cells (Ͼ two cells/section) in the ipsilateral SN 1 week postlesion, whereas at all other time points less than one cell/section could be observed. At 1 week postlesion, counts of ISEL-positive cells in rats receiving 20 g of 6-OHDA were significantly higher than those in rats receiving 5 g of 6-OHDA (5 Ϯ 0.9 cells/section compared with 2.9 Ϯ 0.2 cells/section), as shown in Fig. 5G .
Dose-Dependent Reduction of Dopamine Levels in the Striatum
The results of HPLC determination of dopamine and its metabolites at 8 weeks postlesion are summarized in Table 2. Dopamine levels were significantly lower in the striatum of animals that received 6-OHDA, both at the anterior (ANOVA F 3,18 = 34.8, p Ͻ 0.0001) and middle (F 3,18 = 184.9, p Ͻ 0.0001) levels but not in the accumbens (F 3,18 = 2.79, p Ͻ 0.06). In the group receiving 20 g there was a severe depletion of dopamine (97% of the contralateral side) in the anterior and medial striatum, with a moderate reduction of dopamine content also occurring in the nucleus accumbens (43% of the contralateral side). In rats with 10 and 5 g of 6-OHDA, dopamine loss was severe in the medial striatum (92 and 89% of the contralateral side, respectively), less so in the anterior striatum (80% of the contralateral side), and the nucleus accumbens was preserved (Ͻ 11% of the contralateral side). Dopamine utilization ratios, as calculated using the equation (DOPAC ϩ HVA)/dopamine, were higher in the anterior striatum of rats with 10 and 20 g of 6-OHDA and the middle striatum of rats with 5 and 10 g of 6-OHDA.
Induction of a Stable Turning Response
The response time to the amphetamine and apomorphine is shown in Fig. 6 . In agreement with morphological and biochemical data, animals receiving 20 g of 6-OHDA showed a robust rotation in response to the amphetamine, which was maintained for up to 8 weeks. Apomorphineinduced rotation was first observed 4 weeks after infusion of 20 g of 6-OHDA and also persisted for the duration of the study. The groups receiving 5 and 10 g presented a transient response to amphetamine, suggesting recovery of the striatal dopamine function on the lesion side.
Discussion
Dopamine Lesion Induced by 6-OHDA CED Infusion
In this study we took advantage of the CED method to infuse 6-OHDA and demonstrated the extensive distribution over the rat striatum, its receptor distribution bed. The low rate of infusion (0.2 l/minute) and the small diameter of the cannula (outer diameter 164 m) allowed a wide distribution of 6-OHDA for a severe loss of the TH-immunoreactive cells in the SN with relative sparing of the VTA. rotational response to amphetamine and apomorphine challenges, making the model useful for testing functional therapeutic changes. We observed an acute degeneration of dopamine terminals followed by a delayed death of cell bodies in the SN during a period of several weeks. In addition, because such chemical lesions were quite uniform and stable, therapeutic intervention can be applied prior to or after the 6-OHDA infusion. Thus this model is useful in neuroprotection studies of PD.
Note that the CED of 6-OHDA induced degeneration of the nigrostriatal fibers with minimum damage to the intrinsic striatal neurons. Nonspecific neuronal lesions were found only along the cannula track as shown with NeuN immunohistochemistry. Convection-enhanced delivery has the advantage of homogeneous drug delivery in the gray matter, whereas drug distribution with the aid of a conventional microinjection is characterized by a steep concentration gradient that leads to a limited area. 20 In the present study, the low concentration of 6-OHDA used (Յ 1 g/l) and the slow rate of the infusion demonstrated specific toxicity in the dopamine axons over a relatively large area with minimal tissue damage. Our results were in agreement with data from previous studies in which investigators used a conventional microinjection of 6-OHDA that induced a partial lesion (50-60% cell loss) of the nigrostriatal pathway. 13, 30 Behavioral changes in these studies were unstable with 20 g of 6-OHDA. 6, 17, 28 The limited lesions were probably a consequence of a high rate of injection, with the large cannula causing a reflux of the infusate. 7 Fluoro-Gold infused by the CED method caused moderate to large necrotic areas around the striatal infusion sites, even with a low concentration of the solution (0.05%). Therefore, we used Fluoro-Gold only to estimate the distribution of the neurotoxin infused by CED. Twenty microliters of the Fluoro-Gold solution was distributed throughout the striatum as extensively as the lesion induced by CED of 20 g of 6-OHDA. At least we can presume that the distribution of Fluoro-Gold reflects the extent of an effective dose of 6-OHDA as a chemical neurotoxin taken up by the terminal of the dopamine neurons. More than 80% of TH-immunoreactive neurons were labeled with Fluoro-Gold in A9 (the pars compacta of the SN), whereas fewer neurons were labeled in A10 (the VTA), which is relatively spared in PD. Neurons in A8 (the retrorubral area), which contributes fibers to both the mesostriatal and mesolimbic systems, were more frequently labeled than those in A10. The results of Fluoro-Gold retrograde labeling indicate that the differential effects of 6-OHDA on A9 and A10 dopamine neurons emanated mainly from the differences in distribution, although we must still consider a higher vulnerability to oxidative stress 32 and a higher uptake ratio of 6-OHDA in the A9 neurons.
We did not observe a recovery in the number of TH-immunoreactive cells during the course of the study, indicating that these striatal lesions involved minimal recovery of the TH phenotype of the nigral neurons. Neuronal density gradually decreased in the SN and resulted in 20% survival compared with the intact side 8 weeks postlesion. The 6-OHDA neurotoxicity is still controversial, that is, actual cell death compared with loss of dopaminergic phenotype in the nigral neurons. Bowenkamp, et al., 4 reported that 6-OHDA injected into the medial forebrain bundle caused loss of the TH phenotype (80% loss of the control) rather than cell death (50% loss of the control) by using Fluoro-Gold labeling. In contrast to their observation, Sauer and Oertel, 30 by using an intrastriatal injection of 6-OHDA, demonstrated loss of Fluoro-Gold-labeled cells rather than TH phenotypic loss without cell death. Taken together with data from previous reports and our own observations, one could assert that there are two mechanisms in 6-OHDA neurotoxicity: the slowly progressive neuronal death as shown in the 6-OHDA uptake mechanism in the dopamine terminals, and the TH phenotype loss by the direct effect of 6-OHDA on cell bodies of the dopamine neurons.
Apoptosis of the Nigral Neurons With 6-OHDA CED Infusion
At 1 week postlesion, we identified apoptotic markers in the dopamine neurons of the SN. Although the ISEL procedure may demonstrate false-positive results due to nonapoptotic cell death, the classic morphological features of apoptosis were demonstrated in dopamine neurons with TH immunohistochemistry and Nissl or Hoechst nuclear dye counterstaining. Excitotoxic striatal lesions induce apoptosis of nigral dopamine neurons in the adult brain 27 as well as in the developing brain. 16, 22 Marti, et al., 23 showed that an intrastriatal injection of 6-OHDA during early development induces apoptosis of dopamine neurons 3 to 8 days postlesion by using TH immunostaining, silver staining, and ISEL. Our quantitative data show that intrastriatal CED of 6-OHDA significantly induces apoptosis of the nigral neurons, based on the result that the numbers of apoptotic cells (Ͻ 10 cells/section) are in accordance with data from a previous study. 23 The dose-dependent nature of apoptotic cell counts also supports this view. Results from a recent study in which authors used ISEL and FluoroJade, a marker for neuronal degeneration, demonstrated that the apoptotic feature is maximal at 6 hours postlesion with 6-OHDA injected into the medial forebrain bundle, whereas neuronal degeneration was revealed later. 37 In this study, TH immunoreactivity was observed in the nigral neurons during the course of degeneration. Based on our observation that apoptotic cells occasionally exhibited TH negativity, it is possible that intrastriatal 6-OHDA induces loss of a dopaminergic phenotype prior to expression of the apoptotic features in some of the nigral neurons. Nonetheless, as demonstrated by Joen, et al., 14 intranigral injection of 6-OHDA did not show apoptotic features on TH immunostaining or silver staining, and there is an ongoing discussion of which is prominent in the nigral dopamine neurons with 6-OHDA-apoptosis or necrosis.
Conclusions
In this study we have characterized the time course and extent of cell death in the SN following an intrastriatal CED of 6-OHDA. A dose-dependent loss of dopamine terminals in the striatum was followed by a progressive reduction in the number of the nigral dopamine neurons. Convection-enhanced delivery of 20 g of 6-OHDA induced an extensive and progressive degeneration of dopamine neurons, which could be quantified using morphological, biochemical, and behavioral measurements. Because neuroprotective and regenerative treatments can be applied in the time span between 6-OHDA administration and nigral cell death, this model is useful for testing neuroprotective strategies in PD.
